VENLO, Netherlands, July 27, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2017, delivering on goals for improvements in net sales and adjusted earnings.
"QIAGEN's performance for the second quarter of 2017 further strengthens our confidence in achieving our full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share, as our differentiated portfolio of Sample to Insight molecular testing solutions gains momentum," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
Click here for the full press release
Download the QIAGEN Investor Relations App
Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: firstname.lastname@example.org ir.qiagen.com Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: email@example.com pr.qiagen.com
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All